AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28284221
Drug: Hormonal contraceptive
RxNorm normalized name: HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal contraceptive method (DMPA, oral pills, norplant)
Trial: 23585423
Drug: Enalapril at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril at 0.4 mg/kg/day for 1 year
Trial: 17694046
Drug: Intraligamental injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamental injection (ITR)
Trial: 17694046
Drug: Infiltration injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 0.02 g in 1 mL INFILTRATION INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration injection (IFL)
Trial: 15037668
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous apomorphine therapy at a rate of 4 mg/h
Trial: 15037668
Drug: Intranasal apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal apomorphine (2 to 5 mg per inhalation)
Trial: 15037668
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg subcutaneous apomorphine
Trial: 15037668
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg sublingual apomorphine
Trial: 15037668
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg rectal apomorphine suppository
Trial: 11232013
Drug: Rosiglitazone 2
RxNorm normalized name: rosiglitazone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 2 mg bd
Trial: 11232013
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg bd
Trial: 3165190
Drug: Chemomechanical preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemomechanical preparation (3% H2O2 and 5.25% NaOCl as irrigants, no intracanal medication)
Trial: 27842579
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (OT) before surgical consultation
Trial: 21358087
Drug: RT-HT (Radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT-HT (Radiation Therapy with Hyperthermia)
Trial: 21358087
Drug: RT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT alone (Radiation Therapy)
Trial: 17596638
Drug: Morning or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning or afternoon bright light exposure for 1 hr daily (Monday‐Friday) for 10 weeks
Trial: 10687880
Drug: HRT group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT group: Sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU/day) + calcium lactate (500 mg/day) (n = 232)
Trial: 10687880
Drug: Non-HRT group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HRT group: Calcium lactate (500 mg/day) alone or in combination with vitamin D3 (100-300 IU/day) (n = 232)
Trial: 9210905
Drug: BLP (lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLP (lactobacillus casei preparation)
Trial: 8398322
Drug: Ondansetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (3 doses of 8 mg IV at 0, 4, and 8 hours)
Trial: 8398322
Drug: Metoclopramide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (3 mg/kg IV loading dose followed by 0.5 mg/kg/h for 8 hours)
Trial: 3081361
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) 80 mg aerosolized
Trial: 30257802
Drug: Vorapaxar (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar (2.5 mg orally daily for 12 weeks)
Trial: 27282594
Drug: Local methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local methylprednisolone injections (n=20)
Trial: 22295869
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 20 mg/kg PO q8h for 16 weeks
Trial: 20738476
Drug: Commercially funded
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially funded trials (pharmaceutical companies)
Trial: 19255990
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen suspension (10, 5, 5 mg/kg every 24 hours)
Trial: 9014674
Drug: Sequential avulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential avulsion of the long saphenous vein
Trial: 6435067
Drug: tinnitus instrument
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tinnitus instrument (a combination device consisting of a tinnitus masker and a hearing aid)
Trial: 30001740
Drug: DMARD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD treatment (starting with methotrexate monotherapy with prednisolone bridging)
Trial: 24812043
Drug: Fingolimod 0.5
RxNorm normalized name: fingolimod 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 0.5 mg or 1.25 mg
Trial: 24812043
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon β‐1a (IFNβ‐1a)
Trial: 17289895
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cisplatin and vinorelbine
Trial: 9485087
Drug: 20 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg/day oral type II collagen (CII)
Trial: 9485087
Drug: 100 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg/day oral type II collagen (CII)
Trial: 9485087
Drug: 500 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg/day oral type II collagen (CII)
Trial: 9485087
Drug: 2,500 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,500 microg/day oral type II collagen (CII)
Trial: 2548552
Drug: Cilazapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (5 mg oral)
Trial: 28086917
Drug: Resveratrol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (up to 1 g by mouth twice daily)
Trial: 26338810
Drug: Fingolimod 1.25/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 1.25/5 mg
Trial: 19958431
Drug: Jessner's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jessner's solution peel
Trial: 19958431
Drug: Topical hydroquinone
RxNorm normalized name: hydroquinone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydroquinone 2% and kojic acid
Trial: 1715809
Drug: 1% gamma‐BHC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% gamma‐BHC emulsion at 10.0 ml
Trial: 1715809
Drug: 1% gamma‐BHC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% gamma‐BHC emulsion at 5.0 ml
Trial: 1715809
Drug: 1% gamma‐BHC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% gamma‐BHC emulsion at 2.5 ml
Trial: 1715809
Drug: Overall infestation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall infestation rate 5 months after treatment
Trial: 30776996
Drug: Ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor and Aspirin
Trial: 22826530
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% (10 mL)
Trial: 22826530
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% with dexmedetomidine 1 μg/kg (10 mL)
Trial: 20088935
Drug: YM150 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM150 5 mg
Trial: 17663737
Drug: YM150 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM150 10 mg
Trial: 17663737
Drug: YM150 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM150 30 mg
Trial: 17663737
Drug: YM150 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM150 60 mg
Trial: 20088935
Drug: YM150 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM150 120 mg
Trial: 10463404
Drug: Drop test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drop test with varying test solutions
Trial: 10463404
Drug: Drop test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drop test with increased viscosity of test solution
Trial: 8531592
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bolus (250 micrograms) and infusion (250 micrograms/h for 65 min) of somatostatin
Trial: 26814251
Drug: Alternative method
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative method of local anesthesia injection
Trial: 26814251
Drug: Traditional method
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional method of local anesthesia injection
Trial: 26814251
Drug: Treatment needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment needle size
Trial: 26814251
Drug: Pain at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain at one inch of treatment needle insertion
Trial: 12394202
Drug: Intranasal budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal budesonide, applied to each nostril, once daily for eight weeks
Trial: 8610775
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of intravaginal prostaglandin E2 gel for 5 consecutive days
Trial: 2191763
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (2500 cGy over 5 to 7 days)
Trial: 28836895
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release
Trial: 27409603
Drug: Sarcosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (2 grams daily)
Trial: 9693934
Drug: Metformin (M;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (M; n = 15)
Trial: 1961959
Drug: Propofol, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol, 2.5 mg/kg
Trial: 17171863
Drug: Thiamylal, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal, 4 mg/kg
Trial: 22027664
Drug: Acetyl-L-carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALC) administered in doses from 2250 to 3000 mg per day
Trial: 16532095
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg of elemental zinc/cap/day) for 3 months
Trial: 11361230
Drug: Absorbitol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbitol (250 mg) 3 times a day before meals
Trial: 27367436
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low nicotine cigarettes (VLNCs; 0.4 mg nicotine/g tobacco) for 6 weeks
Trial: 18628485
Drug: CC (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (conventional cigarette)
Trial: 16816829
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS (1 Hz at 110% of motor threshold) administered over the left dorso-lateral prefrontal cortex for 10 sessions.
Trial: 16816829
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS administered over the left dorso-lateral prefrontal cortex for 10 sessions.
Trial: 12932382
Drug: Immediate systemic
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate systemic therapy with oral chlorambucil 10 mg per day continuously
Trial: 12932382
Drug: Observation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation with systemic therapy delayed until disease progression
Trial: 10190655
Drug: Vapreotide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapreotide (1.5 mg day(-1) s.c.) for 7 days
Trial: 2502385
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (20 mg/day for adult)
Trial: 2502385
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (80 mg/day for adult)
Trial: 2502385
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (20 mg/day for adult) in patients with Lennox-Gastaut syndrome
Trial: 2502385
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (80 mg/day for adult) in patients with Lennox-Gastaut syndrome
Trial: 8984133
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg once a day
Trial: 14739127
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid (2 g, n=8)
Trial: 11434163
Drug: Platelet activation
RxNorm normalized name: Platelet activation dependent granule external membrane protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet activation assessment at the onset of INS and after 2 weeks of therapy
Trial: 8042724
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg intramuscularly before surgery, repeated at 4 and 10 hours)
Trial: 8042724
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg intravenously after assessing block height)
Trial: 18443928
Drug: Control (penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (penicillin V, cefuroxime, or amoxicillin/clavulanate)
Trial: 19060427
Drug: Allicor (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allicor (600 mg daily)
Trial: 11171786
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (ramipril 10 mg/d)
Trial: 11171786
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II type 1 receptor antagonist (losartan 100 mg/d)
Trial: 31071249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 6 strains of probiotics for 3 months
Trial: 27876806
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aspirin (ASA)
Trial: 25972532
Drug: 2 portions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 portions of FVs daily (160 g)
Trial: 25972532
Drug: 4 portions
RxNorm normalized name: nonoxynol-9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 portions of FVs daily (320 g)
Trial: 25972532
Drug: 7 portions
RxNorm normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 portions of FVs daily (560 g)
Trial: 11348708
Drug: Hepacare (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepacare (1 month/two dose regimen)
Trial: 11348708
Drug: Engerix-B (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B (2 month/three dose regimen)
Trial: 8424293
Drug: Prophylactic dixyrazine
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dixyrazine 0.25 mg kg‐1 i.v. after surgery
Trial: 27141627
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medication)
Trial: 10198297
Drug: Mixed amino
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amino acid (MAA) solution (40 g)
Trial: 10198297
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acid (EAA) solution (40 g)
Trial: 7775360
Drug: Methylphenidate (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.4 to 1.3 mg/kg per day, mean 0.7 mg/kg per day)
Trial: 7775360
Drug: Bupropion (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (1.4 to 5.7 mg/kg per day, mean 3.3 mg/kg per day)
Trial: 1692095
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with radiation
Trial: 2859523
Drug: Combined radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiation and chemotherapy
Trial: 498151
Drug: cis-platinum (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-platinum (100 mg/m2) administered via rapid infusion (15-minute)
Trial: 498151
Drug: cis-platinum (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-platinum (100 mg/m2) administered via 6-hour infusion
Trial: 498151
Drug: cis-platinum with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-platinum with concomitant administration of mannitol
Trial: 31215242
Drug: Classical oral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical oral Navelbine (once weekly)
Trial: 23648613
Drug: Segmental muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Segmental muscle vibration (SMV) combined with general physical therapy
Trial: 23648613
Drug: General physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General physical therapy (Control)
Trial: 19957513
Drug: Cognitive impairment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive impairment group (serum uric acid level: 249 micromol/L ± 59 micromol/L)
Trial: 19957513
Drug: Non-cognitive impairment
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-cognitive impairment group (serum uric acid level: 323 micromol/L ± 52 micromol/L)
Trial: 15794407
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with Dermatophagoides pteronyssinus (500, 1000, 2000, 5000, 8000, and 10,000 biological units)
Trial: 15794407
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with Dermatophagoides pteronyssinus
Trial: 11142926
Drug: Willow bark
RxNorm normalized name: Willow bark
DrugBank: Willow bark (DB14691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willow bark extract (240 mg salicin/day)
Trial: 9835238
Drug: Treatments recommended
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments recommended by psychiatrists
Trial: 2670536
Drug: ACC-9653 (phenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC-9653 (phenytoin prodrug) intravenous administration
Trial: 2670536
Drug: ACC-9653 (phenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC-9653 (phenytoin prodrug) intramuscular administration
Trial: 2670536
Drug: Sodium phenytoin
RxNorm normalized name: Phenytoin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium phenytoin intravenous administration
Trial: 412590
Drug: 400 rads
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 rads of megavoltage irradiation to the site of the lesion given as a single dose and repeated 7 days later
Trial: 30500603
Drug: Mipomersen 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 70 mg thrice weekly
Trial: 30173291
Drug: Laparoscopic-assisted TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic-assisted TAP block with 30 ml 0.25% Bupivacaine
Trial: 30173291
Drug: Periportal local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periportal local anaesthetic infiltration with 15 ml of 0.5% Bupivacaine
Trial: 27094918
Drug: Chiral bioanalytical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiral bioanalytical method for R‐ibuprofen and S‐ibuprofen
Trial: 24612455
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg/day for at least 3 months (Group 1)
Trial: 27118284
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Group 2)
Trial: 22275272
Drug: [phenyl‐U‐¹⁴C]‐aclidinium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [phenyl‐U‐¹⁴C]‐aclidinium bromide (400 µg, via 5 min infusion)
Trial: 22275272
Drug: [glycolyl‐U‐¹⁴C]‐aclidinium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [glycolyl‐U‐¹⁴C]‐aclidinium bromide (400 µg, via 5 min infusion)
Trial: 20370474
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/day) taken on awakening
Trial: 20370474
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/day) taken at bedtime